Joe Zhang, MD., Ph.D., DABT

Dr. Zhang is a pharmaceutical industry veteran with >20 years of working experience from health authority (CFDA), multinational pharmaceutical companies (Roche and Boehringer Ingelheim), CROs and domestic biotechs with increased roles and responsibilities from scientist to Executive Vice President. He is an expert in pharmaceutical development and seasoned executive with hands on experience of leading R&D teams to successful regulatory filings and experience of dealing with different health authorities to defend dossier and to solve regulatory related issues (INDs/NDAs). He is a review expert of National Key Innovative Drug R&D Projects, the National Health Commission, P. R. China and has drafted/reviewed more than 10 guidelines for NMPA as an invited expert including the guideline on biosimilars issued in February 2015.

Dr. Zhang has professional training from both the United States and China. He received his Ph.D. in Toxicology from Indiana University and is a certified toxicologist by American Board of Toxicology. He also has medical degrees from Beijing Medical University. He is the Vice President of Chinese Society of Quality Assurance and a member of Drug Safety Evaluation Committee of China Pharmaceutical Association. He was the first chair of the Nonclinical Working Group of RDPAC and a member of DIA Advisory Committee China.